Cargando…

Podocyte-Related Mechanisms Underlying Survival Benefit of Long-Term Angiotensin Receptor Blocker

We previously found that short-term treatment (week 8 to 12 after injury) with high-dose angiotensin receptor blocker (ARB) induced the regression of existing glomerulosclerosis in 5/6 nephrectomy rats. We therefore assessed the effects of long-term intervention with ARB vs. nonspecific antihyperten...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Xuejing, Gao, Dan, Albertazzi, Vittorio, Zhong, Jianyong, Ma, Li-Jun, Du, Liping, Shyr, Yu, Kon, Valentina, Yang, Hai-Chun, Fogo, Agnes B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181646/ https://www.ncbi.nlm.nih.gov/pubmed/35682697 http://dx.doi.org/10.3390/ijms23116018

Ejemplares similares

Mineralocorticoid Receptor Blocker Protects against Podocyte-Dependent Glomerulosclerosis
por: Takagi, Nobuaki, et al.
Publicado: (2012)

Intestinal Lymphatic Dysfunction in Kidney Disease
por: Zhong, Jianyong, et al.
Publicado: (2023)

Angiotensin II Receptor Blocker Attenuates Intrarenal Renin-Angiotensin-System and Podocyte Injury in Rats with Myocardial Infarction
por: Wen, Zhu-zhi, et al.
Publicado: (2013)

Maturational Regression of Glomeruli Determines the Nephron Population in Normal Mice
por: Zhong, Jianyong, et al.
Publicado: (2012)

Survival Benefit of Renin-Angiotensin System Blockers in Critically Ill Cancer Patients: A Retrospective Study
por: Laghlam, Driss, et al.
Publicado: (2023)

Impact of Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers and Thiazide Diuretics on Survival of Ovarian Cancer Patients
por: Cho, Min Ae, et al.
Publicado: (2020)

Re: Is there a difference in the effect between the angiotensin‐converting enzyme inhibitor and angiotensin‐receptor blocker on the COVID‐19?
por: Liu, Xiao, et al.
Publicado: (2020)

Angiotensin II Modulates Podocyte Glucose Transport
por: Lewko, Barbara, et al.
Publicado: (2018)

Is angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy protective against prostate cancer?
por: Mao, Yeqing, et al.
Publicado: (2016)

Association of Renin-Angiotensin System Blockers with Survival in Patients on Maintenance Hemodialysis
por: Kang, Seok Hui, et al.
Publicado: (2023)

Renal progenitor cells modulated by angiotensin II receptor blocker (ARB) medication and differentiation towards podocytes in anti-thy1.1 nephritis
por: Wu, Di, et al.
Publicado: (2020)

Reference genes for mesangial cell and podocyte qPCR gene expression studies under high-glucose and renin-angiotensin-system blocker conditions
por: Hosni, Nicole Dittrich, et al.
Publicado: (2021)

Effects of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors on COVID-19
por: Li, Xiao-Long, et al.
Publicado: (2021)

Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta‐blockers in patients hospitalized for acute heart failure
por: Carubelli, Valentina, et al.
Publicado: (2021)

Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension
por: Bisognano, John D, et al.
Publicado: (2007)

Angiotensin receptor blocker add-on therapy in portal hypertension: To use angiotensin receptor blocker or not to use, that is the question
por: Lee, Hyun Woong
Publicado: (2014)

Angiotensin II induces cholesterol accumulation and injury in podocytes
por: Yang, Yingjie, et al.
Publicado: (2017)

Possible Benefit of Angiotensin II Receptor Blockers in COVID-19 Patients: A Case Series
por: Lee, Su Jin, et al.
Publicado: (2021)

Combination of Tripterygium wilfordii Hook F and angiotensin receptor blocker synergistically reduces excretion of urinary podocytes in patients with type 2 diabetic kidney disease
por: Ma, Ruixia, et al.
Publicado: (2015)

Angiotensin receptor blockers and COVID-19
por: Saavedra, Juan M.
Publicado: (2020)

Angiotensin receptor blocker neprilysin inhibitors
por: Usuda, Daisuke, et al.
Publicado: (2021)

Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
por: Danser, A.H. Jan, et al.
Publicado: (2020)

Fixed-Dose Combinations of Renin–Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension: A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors
por: Hsiao, Fu-Chih, et al.
Publicado: (2015)

Role of c-Abl and nephrin in podocyte cytoskeletal remodeling induced by angiotensin II
por: Ma, Yiqiong, et al.
Publicado: (2018)

Chronic kidney disease alters lipid trafficking and inflammatory responses in macrophages: effects of liver X receptor agonism
por: Kaseda, Ryohei, et al.
Publicado: (2018)

The Combination of Beta Blockers and Renin-Angiotensin System Blockers Improves Survival in Incident Hemodialysis Patients: A Propensity-Matched Study
por: Luño, José, et al.
Publicado: (2017)

Impact of Angiotensin I-converting Enzyme Inhibitors and Angiotensin II Type-1 Receptor Blockers on Survival of Patients with NSCLC
por: Miao, Lili, et al.
Publicado: (2016)

Premorbid Use of Beta-Blockers or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients with Acute Ischemic Stroke
por: Zeng, Yuanyuan, et al.
Publicado: (2023)

COVID-19, Angiotensin Receptor Blockers, and the Brain
por: Saavedra, Juan M.
Publicado: (2020)

Renin-angiotensin system blockers and COVID-19
por: Vidal-Petiot, Emmanuelle, et al.
Publicado: (2021)

The use of angiotensin receptor blockers in dementia prevention
por: Müller, Jordana de Araujo, et al.
Publicado: (2023)

Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
por: Zhang, Chao, et al.
Publicado: (2021)

The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Moretti, Myla E., et al.
Publicado: (2012)

Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels
por: Ajmal, Adnan, et al.
Publicado: (2013)

Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide
por: Mamdani, Muhammad, et al.
Publicado: (2019)

Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers—Relevance to COVID-19
por: Moore, Graham J., et al.
Publicado: (2021)

A combined role of calcium channel blockers and angiotensin receptor blockers in stroke prevention
por: Wang, Ji-Guang
Publicado: (2009)

Comparison of clinical outcomes of angiotensin receptor blockers with angiotensin-converting enzyme inhibitors in patients with acute myocardial infarction
por: Chen, Chih-Wei, et al.
Publicado: (2023)

The Role of Angiotensin II in Glomerular Volume Dynamics and Podocyte Calcium Handling
por: Ilatovskaya, Daria V., et al.
Publicado: (2017)

PFKFB3 downregulation aggravates Angiotensin II-induced podocyte detachment
por: Huang, Xiaoxiao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bs8ut756du41aed1mo89q8lh4g